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Abstract 
Dexamethasone is a synthetic glucocorticoid which can be used to 
suppress the levels of glucocorticoids in the body. Thus the dexamethasone 
suppression test is used to evaluate the function of the negative feedback control 
of the hypothalamic-pituitary-adrenal axis (HPA axis). While a protocol for 
dexamethasone suppression testing in rats and humans has been established, an 
acceptable program for administration of dexamethasone to mice was lacking. In 
this study, mice transgenic for growth hormone, which are hypothesized to 
exhibit abnormal HPA control, and their normallittermates were used in three 
different trials in an attempt to examine the effects of dexamethasone on adrenal 
corticosterone secretion in mice. The first trial involved PEPCK;-hGH transgenic 
mice and their normal siblings. First, an orbital sinus puncture under ether 
anesthesia was taken at 0700 hrs in order to obtain a basal level of corticosterone. 
A subcutaneous injection of 0.2 ug dexamethasone 21-phosphate (DEX) /lOOg 
body weight was administered at 0800 hrs, and another orbital sinus puncture 
was taken 4 hours later. The second trial followed similar procedure but used 
MT-hGH transgenic mice and their normal siblings. It was concluded that the 
dosage of dexamethasone was insufficient in these trials since levels of 
corticosterone were higher at four hours post injection than at the basal time. 
Therefore a tenfold increased dosage (2.0 ug DEX/lOOg body weight) was used 
for the third trial. Normal siblings of transgenic mice were randomly assigned to 
either a dexamethasone or saline injection group. In addition to basal levels, 
corticosterone levels were measured at two and four hours post injection. The 
results of this experiment showed that plasma corticosterone levels in mice 
treated with dexamethasone were lower than in the saline control group. 
However, levels at post times for both groups were still elevated in comparison 
to basal levels. At four hours post, the dexamethasone group showed levels near 
the basal while the saline group was still significantly elevated. Therefore, 
adminstering 2.0ug dex/lOOg body weight significantly suppresses levels of 
corticosterone in mice. The issue still remains, however, why levels increased at 
two and four hours post injection. Further study is necessary to determine if this 
rise is a response due to the stress of ether, orbital sinus puncture, and handling 
or if it is perhaps a natural rise preceding the peak of corticosterone levels in the 
early evening. 
Introduction 
The hypothalamic-pituitary-adrenal axis (HPA axis) plays a vital role in 
coordinating daily activities and regulating an animal's response to Stressors [2]. 
This study focuses primarily on HPA axis mediation of glucocorticoid levels. In 
response to a perceived stress, the release of corticotropin releasing factor (CRF) 
is triggered in the mediobasal hypothalamus. CRF then travels thru a portal 
system to the anterior pituitary where it supports the synthesis and release of 
adrenocorticotropic hormone (ACTH). In tum, ACTH stimulates the synthesis 
and release of glucorticoids from the adrenals. Once in the circulation, 
glucorticoids, such as corticosterone in mice or cortisol in humans, lead to 
lipolysis, glycogenolysis, and protein catabolism. Hence, the animal has 
increased energy available to cope with a stressor. [4] Additionally, the 
glucocorticoids act on receptors in the hypothalamus and pituitary to inhibit the 
release of CRF and ACTH [6]. Thus, the HPA axis operates as a closed-loop 
negative feedback system in order to regulate glucocorticoids as shown in Figure 
1. 
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Figure 1: The hypothalamic-pituitary-adrenal feedback system 
Studies have shown that there are various conditions that seem to alter the 
functioning of the HPA axis by disrupting the feedback system and consequently 
leading to chronically elevated glucocorticoid levels. In humans these 
conditions include depression, Alzheimer's disease, and other dementias [4,6]. 
The effects of aging on the HPA axis has received much attention and numerous 
studies have shown elevated basal glucocorticoid levels as well as increased HPA 
axis reactivity to stress in aged rats [2,3,4,5.8]. Prolonged elevation of 
glucocorticoids are harmful due to its catabolic effects. Suppression of anabolic 
processes, muscle atrophy, decreased sensitivity to insulin, increased risk of 
steroid induced diabetes, hypertension, hyperlipidemia, hypercholesterolemia, 
arterial disease, amenorrhea, infertility, impairment of growth and repair of 
tissue, prolonged immune suppression, and osteoporosis are all associated with 
chronically high levels of glucocorticoids [4]. 
In addition to age and dementia effecting HPA axis activity, it has been 
shown that several strains of mice transgenic for growth hormone also 
demonstrate HPA functional abnormalities. Bartke et al. found corticosterone 
levels in these transgenic mice that were congruent to levels found in normal 
mice of a much greater chronological age [1]. Furthermore, these transgenic mice 
show a prolonged elevation of glucocorticoid levels in response to stress [Steger, 
R.W. and Bartke, A., unpublished]. Therefore, it seems mice transgenic for 
growth hormone exhibit the effects of aging on the HPA axis prematurely. 
In order to explain the increased HPA axis activity in mice transgenic for 
growth hormone it has been hypothesized that the glucocorticoid feedback 
mechanism does not function properly in these animals. Dexamethasone (DEX) 
is a synthetic glucocorticoid that suppresses CRF, ACTH, and thus plasma 
corticosterone levels in the same manner as corticosterone. Therefore, 
dexamethasone suppression tests can be used to assess the functioning of the 
glucocorticoid feedback system, which is necessary to test this hypothesis. 
Dexamethasone suppression tests are commonly used in humans for 
clinical psychiatry and a protocol for such testing in rats has been established 
[6,9]. However, an acceptable program for adminstering dexamethasone to mice 
was lacking. Therefore, as a first step in studying the HPA axis feedback control 
in mice transgenic for growth hormone, the goal of this project was to establish a 
protocol for dexamethasone suppression testing in mice. 
Materials and Methods 
Transgenic mice were originally produced by microinjection of hGH gene 
fused to rat phosphoenolpyruvate carboxykinase promoter/regulator (for 
PEPCK-hGH mice) or mouse metallothionein-l promoter (for MT-hGH mice) into 
the pronuclei of fertilized mouse eggs as previously described [9]. Lines of 
transgenic mice were then produced by mating a male mouse positive for hGH 
expression with B6C3 F1 hybrid females as previously described [9]. 
Mice used in this study were housed 4 to 5 per cage in a temperature 
controlled room (22· C) on a 12:12 lightdark schedule (lights on at 0600h). Food 
(TekLad 6% Rat/Mouse Diet 002, containing a minimum of 24% protein and 6% 
fat and a maximum of 5% fiber, Teklad Premier; Harlan Sprague-Dawley, 
Madison, WI) and tap water were provided ad libitum. In each trial, the mice 
were handled four of seven days during the week prior to experimentation. 
TRIAL I 
Mice used in this trial were PEPCK-hGH transgenic males or their normal 
male siblings. At 0600h mice were transferred from the vivarium to the 
laboratory. In order to prevent the stress of transfer from confounding results, 
the mice were not handled in the new environment for one hour. Then, 
beginning at 0700 hours each mouse was anesthetized with ether and basal blood 
samples were rapidly taken by orbital sinus puncture. EDTA (10.0 uL) was used 
in each sample as an anticoagulant. Subcutaneous injections of dexamethasone 
21-phosphate (Sigma Pharmaceuticals, St. Louis, MO.) dissolved in saline began 
at 0800h. Each mouse received 0.2 ug DEX/lOO g.b.w. according to the 
procedure for rats previously described [7]. Four hours post injection with DEX 
animals were anesthetized and blood samples taken for the second time. All 
blood samples were centrifuged at 2500 g for 15 minutes and the separated 
plasma was frozen until analysis. Animals were allowed to recover and then 
returned to the vivarium. The mice continued to be handled throughout the 
following week. 
Seven days after the original experiment, mice were randomly assigned to 
control or dexamethasone groups with an approximately equal number of 
normals and transgenics in each group. The mice were transferred at 0700h this 
time, with injections beginning at 0800h. The injections followed the same 
procedure as above except that controls received saline only. Four hours post 
injection the animals were sacrificed by decapitation and trunk blood collected. 
Again, EDTA (100 uL for normal mice or 200uL for transgenic mice)was used as 
an anticoagulant, samples were centrifuged, and plasma frozen until analysis. 
TRIALll 
Trial II followed the identical procedure as described for Trial I except that 
the mice used were males transgenic for MT-hGH or their normal siblings. 
TRIAL ill 
For Trial ill the normal male siblings of mice transgenic for growth 
hormone were used. The mice were randomly assigned to either control or 
dexamethasone groups. Then the members of each of those groups were 
randomly assigned to either a 2 or 4 hour group (indicating the time elapsed 
between injection and blood sample collection) such that the 2 and 4 hour groups 
consisted of approximately the same number of controls and dexamethasone 
group members. Mice were transferred at 0600h. Animals were anesthetized 
with ether and blood samples collected by orbital sinus puncture at 0700h. 
Injections began at 0800h. This time the dosage was 2.0 ug DEX/lOOg.b.w. for 
the dexamethasone group while controls received saline injections. Then the 2 
hour group animals were sacrificed by decapitation and trunk blood collected 
beginning at 1000h. The 4 hour group members were similarly sacrificed 
beginning at 1200h. Samples were handled as described above. 
CORTICOSTERONE ASSAY 
Serum samples were analyzed for corticosterone concentration by 
radioimmunoassay using a commercially available kit (ICN Pharmaceuticals, 
Inc., Cost Mesa, CA.). Instructions provided with the kit were followed with the 
following modifications: 
1. The 1:200 dilution of mouse serum with steroid diluent was made by 
taking 5.0 uL of sample to 1.0 mL. 
2. All of the remaining volumes used throughout the procedure were 
divided by two. 
The assay is effective for concentrations ranging from 25 ng/ml to 1000 ng/ml 
with an intraassay variation of approximately 5%. All samples from a single trial 
were run in duplicate in the same assay. 
Additionally, an assay was run in order to determine the amount of assay 
cross-reaction with dexamethasone to ensure that the assay was appropriate for 
dexamethasone suppression testing. This was done by using concentrations of 
dexamethasone ranging from 0.10 ng to 100 ng DEX in a corticosterone assay. 
Results 
The antibody used in the corticosterone assay showed no cross reaction 
with dexamethasone. 
TRIAL I 
Plasma corticosterone levels were elevated in PEPCK-hGH trangenic mice 
as compared to normals (Fig 2). Plasma corticosterone did not decrease, and 
actually showed an increase, after injection of 0.2 ug DEX/lOO g.b.w. for both 
groups of mice. Animals injected with 0.2 ug DEX/lOO g.b.w. exhibited slightly 
higher levels of plasma corticosterone than those treated with saline but the 
results were not significant. 
TRlALII 
Similar to results in Trial I, corticosterone levels in normal and MT-hGH 
transgenic mice were increased after injecton with 0.2 ug DEX/lOO g.b.w. (Fig 4). 
Animals injected with 0.2 ug DEX/IOO g.b.w. had slightly lower levels of 
corticosterone relative to animals injected with saline (Fig 5). 
TRIAL ill 
As depicted in Figure 6, mice treated with 2.0 ug DEX/lOO g.b.w. 
exhibited significantly lower plasma corticosterone levels at two and four hours 
post injection than did mice treated with saline. Also, animals from both the 
saline and DEX groups showed elevated corticosterone levels at times after 
injection in comparison to basal levels, but this elevation was only significant for 
the saline treated mice. 
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Figure 2: Plasma corticosterone levels of normal and PEPCK-hGH transgenic 
mice at basal time and 4 hours after injection of 0.2 ug DEXjlOO g.b.w. 
(mean±SEM) 
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Figure 3: Plasma corticosterone levels of normal and PEPCK-hGH transgenic 
mice 4 hours after injection with saline or 0.2 ug DEX/lOO g.b.w. (mean±SEM) 
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Figure 4: Plasma corticosterone levels of normal and MT-hGH transgenic mice at 
basal time and 4 hours after injection with 0.2 ug DEX/IOO g.b.w. (mean±SEM) 
• Saline 
IBl Dexamethazone 
400 
~ 
E.... 300  
c  '" ~ 
.. 
c 
0 
~-..U> 200 
0 
U 
;; 
0 
~ 
u 
.. 
E 100 
U>.. 
Q. 
04--
N T 
Figure 5: Plasma corticosterone levels of normal and MT-hGH transgenic mice 4 
hours after injection with saline or 0.2 ug DEX/lOO g.b.w. (mean±SEM) 
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Figure 6: Plasma corticosterone levels of normal mice prior to and two or four 
hours after injection with saline or 2.0 ug DEX/lOO g.b.w. (mean±SEM) 
Discussion 
In an attempt to study the functional abnormalities of HPA axis activity 
found in mice transgenic for growth hormone, several trials of dexamathesone 
suppression tests were conducted. The lack of suppression of plasma 
corticosterone levels seen in Trial I and Trial II indicates that the 0.2 ug DEX/lOO 
g.b.w. dosage recommended for rats by Oxenkrug is insufficient for suppressing 
corticosterone levels in mice. This may be due to the increased metabolic rate of 
mice. However, the significant amount of glucocorticoid suppression exhibited 
by the mice treated with DEX in Trial ill indicates that a 2.0 ug DEX/100 g.b.w. 
dose is sufficient for corticosterone suppression testing in mice. 
The results of this experiment raise many questions and provide direction 
for further research. The efficiency of the negative feedback control of adrenal 
corticosterone secretion in mice transgenic for growth hormone has yet to be 
assessed by dexamethasone suppression testing; but the procedure described in 
Trial ill can be used for such assessment. Also, data from Trial I and Trial II 
provide further evidence of elevated plasma corticosterone levels in these 
trangenic mice relative to normal mice. 
Of further interest is the rise in plasma corticosterone levels over the four 
hour testing period illustrated in Figure 6. Most likely these animals were 
stressed by ether, orbital sinus puncture, or injection causing increased 
corticosterone secretion. Rapid sampling of blood after anesthetization should 
not have allowed sufficient time for circulating levels of corticsosterone to be 
affected, but after the first sampling the animals may have had memory of the 
stress and reacted to handling. Further study is necessary to determine if this 
rise in plasma levels of corticosterone is indeed due to stress or some other factor 
such as a natural daily rise preceeding the peak of corticosterone levels in the 
early evening. Perhaps if blood samples and injections could be done via 
cannules this confounding of results might be avoided. However, cannulation is 
very tedious and impractical in mice. 
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